Covidien’s Project ADOPT: Moving The Needle On MIS

In an interview with Medtech Insight, Michael Tarnoff, Covidien’s corporate chief medical officer, discusses how Covidien hopes to drive growth in the market for minimally invasive surgical products through Project ADOPT, the company’s latest strategy for increasing physician adoption of MIS.

As a leader in minimally invasive surgery (MIS) products, Medtronic Minimally Invasive Therapies is known as an innovator in this field and a strong advocate for increased physician adoption of MIS techniques. However, despite the wealth of evidence demonstrating the benefits of MIS, less than 30% of the 15-20 million potential procedures of interest to Covidien’s advanced surgical technologies business are performed via a minimally invasive approach. Michael Tarnoff, MD, Covidien’s corporate chief medical officer, says industry has not significantly moved the needle on MIS adoption because industry-sponsored surgeon education programs have been missing a key component. During the company’s September 2013 Analyst Day presentation, Tarnoff discussed that key component and how Covidien hopes to fill the gaps in surgical education through Project ADOPT (Assuring and Defining Outcomes through Procedural Training), the company’s latest initiative for increasing physician adoption of MIS. To find out more, Medtech Insight spoke with Tarnoff, who provided additional details about Project ADOPT and how it ties in with the company’s plans to drive growth in this market.

Medtech Insight: During Covidien’s September 2013 Investor Day presentation, you discussed a new program, Project ADOPT, to enable new growth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

Industry Execs Talk Tariff Turbulence During MD&M East

 

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

India-UK Free Trade Agreement Sets Stage For Medtech Growth, But Industry Demands Safeguards

 
• By 

Announced after three years of negotiation, the FTA eliminates tariffs on 99% of Indian product types, covering nearly all trade value, and reduces tariffs on 90% of UK products. Although not yet formally signed, the deal is being positioned by the Indian government as “transformative,” with an estimated economic impact of $6.4bn for the UK alone by 2040.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

More from Geography

UK Healthtech Center Of Excellence Given Key MHRA Digital Regulation Role

 
• By 

Ahead of the 11 June UK spending review and its anticipated funding uplift for healthcare and life sciences, the MHRA announced an expansion of its digital expertise by creating a dedicated hub in Leeds, a renowned center of medtech excellence.

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

Aneira Health Launches New Precision Medicine Platform Exclusively For Women

 

Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.